Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375139 | 1.00 | SLC1A1 (0.65) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL10705141 | 1.00 | SLC1A1 (0.65) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL383365 | 0.98 | SLC1A1 (0.64) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL7355918 | 0.98 | SLC1A1 (0.64) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL29398484 | 0.91 | SLC1A3 (0.58) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL14381151 | 0.89 | SLC1A3 (0.56) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL14335621 | 0.88 | SLC1A3 (0.55) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL7243772 | 0.88 | SLC1A3 (0.55) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| SCHEMBL5019077 | 0.87 | LMNA (0.59) | SLC1A1SLC1A3LMNASMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL7243767 | 0.87 | SLC1A3 (0.54) | SLC1A1SLC1A3LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | claimed |
| CN-117510352-A | Synthesis method of D-2, 3-diaminopropionic acid | 浙江永太科技股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2415766-A1 | METHOD FOR MANUFACTURING BENZODIAZEPINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| CN-100379718-C | N alpha-Boc-N beta-Cbz-L-2,3 diaminopropionic acid derivative synthesis method | UNIV WUHAN (CN) | 2008-04-09 | — | — | CN | disclosed |
| EP-1135374-B9 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1135374-B1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| WO-1994008608-A1 | AMINO ACID CONJUGATES OF CYCLOHEXAPEPTIDYL AMINES | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0293071-B1 | REDOX AMINO ACIDS AND PEPTIDES CONTAINING THEM | UNIVERSITY OF FLORIDA (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993012138-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SCHERING CORPORATION (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5079366-A | To derivatize pharmaceutical peptides for transport across the blood/brain barrier | UNIVERSITY OF FLORIDA (US) | 1992-01-07 | — | — | US | disclosed |
| US-4888427-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX SYSTEM | UNIVERSITY OF FLORIDA (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0293071-A1 | Redox amino acids and peptides containing them | UNIVERSITY OF FLORIDA (US) | 1988-11-30 | — | — | EP | disclosed |
| EP-0083923-B1 | AMINOACYL-CONTAINING DIPEPTIDE DERIVATIVES USEFUL AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1988-10-19 | — | — | EP | disclosed |
| US-4555502-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | disclosed |
| EP-0009728-A1 | Hemostatic and platelet increasing agent containing alpha, beta-diaminopropionic acid and derivatives thereof | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | GABRA5, CYP3A5, GABRA1 | SLC1A1 1472/4885SLC1A3 1768/4885LMNA 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.